First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer
Timothy A. Yap(Royal Marsden Hospital), Komal Jhaveri(Memorial Sloan Kettering Cancer Center)
Cited by 12
Related Papers
Poly(ADP-Ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic
|CA A Cancer Journal for Clinicians|2011|209
Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study
|Clinical Cancer Research|2021|134
Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results
|Nature Medicine|2023|100
Ataxia-Telangiectasia Mutated Loss-of-Function Displays Variant and Tissue-Specific Differences across Tumor Types
|Clinical Cancer Research|2024|11